REVERSAL THERAPEUTICS INC

Biotech · Private

PILLAR[6]MAXQ (P6AS), a supramolecular sequestration molecule for reversing neuromuscular blocking agents

Grants
$368K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Investigating the safety and efficacy of pillararene sulfates as novel and effective reversal agents for both steroidal and non-steroidal neuromuscular blocking agents.$368,367
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3003AAIIT LLC——
3004Structure Therapeutics——
3005Provivi Inc.—$77M
3006REVERSAL THERAPEUTICS INC——
3007EARNANO, LLC——
3008SPEKCITON BIOSCIENCES LLC——
3009MONTANA MOLECULAR, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.